

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/TBBC2A18FEDEN.html>

Date: August 2018

Pages: 71

Price: US\$ 3,500.00 (Single User License)

ID: TBBC2A18FEDEN

Abstracts

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018

SUMMARY

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.

The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-

kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response.

OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 2, 5 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Colorectal Cancer, Renal Cell Carcinoma, Atopic Dermatitis (Atopic Eczema), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Cervical Cancer, Endometrial Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer, Hematological Tumor, Hepatitis B, Hypopharyngeal Cancer, Laryngeal Cancer, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX

Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)

The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects

The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development

AbbVie Inc

Abeome Corp

Alligator Bioscience AB

Apogenix AG

BioInvent International AB

Bristol-Myers Squibb Co

Denceptor Therapeutics Ltd

GigaGen Inc

GlaxoSmithKline Plc

Incyte Corp

Innovent Biologics Inc

Invenra Inc

Kyowa Hakko Kirin Co Ltd

MedImmune LLC

Pfizer Inc

Zai Lab Ltd

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles

ABBV-368 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABM-193 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATOR-1015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Agonize TNFRSF4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + tavolimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize OX40 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-3174998 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HuOHX-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBI-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCAGN-1949 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KHK-4083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize OX40L Receptor for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OrthomAb - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04518600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCB-340 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tavolimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tavolimab + tremelimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZL-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones

Featured News & Press Releases

Jul 25, 2018: Innovent receives IND approval to initiate clinical trials in china with its anti-OX40 Agonistic Antibody IBI101

Jul 19, 2018: Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody

Apr 17, 2018: Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation

Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015

Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015

May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US

conference; - Strong new preclinical findings for ATOR-1015

Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May

Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting

Nov 30, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors

Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting

Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment

Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by Abeome Corp, H2 2018
Pipeline by Alligator Bioscience AB, H2 2018
Pipeline by Apogenix AG, H2 2018
Pipeline by BioInvent International AB, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Denceptor Therapeutics Ltd, H2 2018
Pipeline by GigaGen Inc, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Innovent Biologics Inc, H2 2018
Pipeline by Invenra Inc, H2 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Zai Lab Ltd, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

AbbVie Inc
Abeome Corp
Alligator Bioscience AB
Apogenix AG
BioInvent International AB
Bristol-Myers Squibb Co
Denceptor Therapeutics Ltd
GigaGen Inc
GlaxoSmithKline Plc
Incyte Corp
Innovent Biologics Inc
Invenra Inc
Kyowa Hakko Kirin Co Ltd
MedImmune LLC
Pfizer Inc
Zai Lab Ltd

I would like to order

Product name: Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/TBBC2A18FEDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TBBC2A18FEDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970